print page

PL-3994 for Refractory Hypertension

PL-3994, discovered and developed by scientists at Palatin Technologies, is a natriuretic peptide receptor A (NPRA) agonist compound.  Developed initially for the treatment of congestive heart failure (CHF), PL-3994 has successfully completed both a Phase 1 and Phase 2a trial.

Refractory or resistant hypertension is high blood pressure not adequately controlled by current therapies, such as a three-drug regimen that includes a diuretic.  Refractory hypertension is often found in patients with heart failure or renal disease, and puts patients at increased risk for major cardiovascular events.  

PL-3994 lowers blood pressure through a mechanism different than currently approved agents, and acts through the NPRA system.  Data from the Phase 2a trial suggests that PL-3994 acts synergistically with ACE inhibitors, a class of pharmaceuticals used primarily to treat hypertension and congestive heart failure.  This suggests that PL-3994 could be administered as an adjunct to standard therapy in patients with refractory hypertension.

PL-3994 is a synthetic molecule, incorporating a novel and proprietary amino acid mimetic developed by Palatin Technologies.  PL-3994 has an extended half-life, with reduced affinity for natriuretic peptide clearance receptors and increased resistance to neutral endopeptidase, an endogenous enzyme that degrades natriuretic peptides. The result is a drug with improved pharmacokinetic and pharmacodynamic properties.